January 26, 2021 Chemicals, Reagents & Kits Clinical Research/Diagn. Lab Top-10 Life Science Tools Product Launch

PerkinElmer Launches Industry-First GPCR TR-FRET Binding Assay and Beta-Arrestin Kits to Help Advance Therapeutics Discovery

New offerings join PerkinElmer’s leading GPCR Portfolio across characterization and screening assays, screening libraries and workflow optimization WALTHAM, Mass. – January 26, 2021 –PerkinElmer, a global leader committed to innovating for a healthier world, today announced the addition of new assay kits to help further GPCR      (G Protein-Coupled Receptor) therapeutic discovery. The new PerkinElmer offerings... Read more

January 21, 2021 Clinical Research/Diagn. Licensing, IP, and Legal Life Science Tools

Fluidigm Receives CE-IVD Mark for Its Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Assay for COVID-19

Jan 21, 2021 SOUTH SAN FRANCISCO, Calif., Jan. 21, 2021 (GLOBE NEWSWIRE) — Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that the company has received the CE-IVD mark for its Advanta™ Dx SARS-CoV-2 RT-PCR Assay, an extraction-free saliva-based test to detect nucleic acid from the SARS-CoV-2 virus.... Read more

January 21, 2021 Clinical Research/Diagn. M&A, Partnerships Mass Spectrometry

SCIEX Acquires Intabio, a developer of precision solutions for biotherapeutic analysis through imaged cIEF-MS

Innovative charged variant analysis accelerates biologic drug development, ensuring drug safety and efficacyJanuary 21, 2021 12:00 PM Eastern Standard Time FRAMINGHAM, Mass.–(BUSINESS WIRE)–SCIEX, a global leader in life science analytical technologies, announced the closing of its acquisition of Intabio, Inc., a privately held company and the developer of the Blaze™ System for biotherapeutic analysis and quality... Read more

January 21, 2021 Chemicals, Reagents & Kits Clinical Research/Diagn. Life Science Tools

Sales of Novel Coronavirus PCR Testing Reagent Kits outside Japan Exports Began

January 21, 2021 Shimadzu Corporation will begin fully rolling out sales of the novel coronavirus (SARS-CoV-2) detection reagent kits outside Japan. On January 19th, Shimadzu obtained provisional authorization from the Singapore Health Sciences Authority (HSA) to sell the kits and will start exporting the kits to Southeast Asian markets through Shimadzu (Asia Pacific) Pte. Ltd.,... Read more

January 19, 2021 Bio/Pharma/CRO Clinical Research/Diagn. Lab Top-10

Thermo Fisher Scientific to Acquire Point-of-Care Molecular Diagnostics Provider Mesa Biotech

Thermo Fisher Scientific to Acquire Point-of-Care Molecular Diagnostics Provider Mesa Biotech WALTHAM, Mass., Jan. 19, 2021 /PRNewswire/ — Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced it has entered into a definitive agreement to acquire Mesa Biotech, Inc., a privately held molecular diagnostic company, for approximately $450 million in cash.... Read more

January 13, 2021 Clinical Research/Diagn. Life Science Tools

Pacific Biosciences and Invitae to Develop Ultra-High-Throughput Clinical Whole Genome Sequencing Platform

MENLO PARK, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq: PACB), a leading provider of high-quality, long-read sequencing platforms, today announced a multi-year collaboration with Invitae Corporation (NYSE: NVTA), a leading medical genetics company, to begin development of a production-scale high-throughput sequencing platform leveraging the power of PacBio’s highly accurate... Read more

January 13, 2021 Clinical Research/Diagn. Life Science Tools

Pacific Biosciences and Invitae to Develop Ultra-High-Throughput Clinical Whole Genome Sequencing Platform

MENLO PARK, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq: PACB), a leading provider of high-quality, long-read sequencing platforms, today announced a multi-year collaboration with Invitae Corporation (NYSE: NVTA), a leading medical genetics company, to begin development of a production-scale high-throughput sequencing platform leveraging the power of PacBio’s highly accurate... Read more

January 13, 2021 Clinical Research/Diagn. Life Science Tools

Pacific Biosciences and Invitae to Develop Ultra-High-Throughput Clinical Whole Genome Sequencing Platform

MENLO PARK, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq: PACB), a leading provider of high-quality, long-read sequencing platforms, today announced a multi-year collaboration with Invitae Corporation (NYSE: NVTA), a leading medical genetics company, to begin development of a production-scale high-throughput sequencing platform leveraging the power of PacBio’s highly accurate... Read more

January 11, 2021 Clinical Research/Diagn. Environ, Ag./Food & Bev Lab Top-10 Licensing, IP, and Legal M&A, Partnerships Product Launch

Illumina Announces New and Expanded Oncology Partnerships with Bristol Myers Squibb, Kura Oncology, Myriad Genetics, and Merck to Advance Comprehensive Genomic Profiling

SAN DIEGO–(BUSINESS WIRE)–With genetic sequencing at the forefront of precision medicine, Illumina (NASDAQ: ILMN) is pleased to announce a portfolio of new and expanded oncology partnerships that further the company’s commitment to develop standardized, globally distributable tools for precision oncology. Speaking today at the 39th Annual J.P. Morgan Healthcare Conference in San Francisco, California, Illumina... Read more

January 7, 2021 Clinical Research/Diagn. Life Science Tools M&A, Partnerships

MilliporeSigma Acquires AmpTec to Expand mRNA Capabilities for Vaccines, Treatments and Diagnostics

Adds to MilliporeSigma’s lipid manufacturing expertise, providing an integrated offering across mRNA value chain AmpTec’s differentiated polymerase chain reaction (PCR)-based technology has shown to have advantages over other technologies for mRNA manufacturing Diagnostics business focused on producing customized long RNAs and DNAs for in vitro diagnostics, complements existing MilliporeSigma portfolio Burlington, Massachusetts, January 7, 2020 — MilliporeSigma today... Read more